Inspira announced that the INSPIRA ART100 has been approved by Israel’s largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures. As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration approved INSPIRA ART100 system at one of Israel’s renowned medical centers affiliated with the largest health care provider. A team of pioneering physicians at a renowned medical center has requested to validate the INSPIRA ART100 system for application in highly complex organ transplant procedures. This deployment will allow leading Israeli transplant specialists to gain hands-on experience with Inspira’s innovative technology, specifically exploring its potential to maintain organ viability through advanced blood oxygenation. The INSPIRA ART100 system may serve a unique role by providing out of body blood oxygenation to keep the patient alive during the organ transplant procedure as well as for several hours in the recovery room.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Achieves Breakthrough in VORTX Testing
- Inspira Technologies achieves 99% gas exchange efficiency in VORTX
- Inspira Technologies Achieves First Revenue Milestone with INSPIRA ART100 Deployment
- Inspira generates first revenues from deployment of INSPIRA ART100 systems
- Inspira Technologies Expands Share Offering Capacity in April 2025